Document Detail


Use of orally administered anhydrous crystalline maltose for relief of dry mouth.
MedLine Citation:
PMID:  11246934     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To examine the safety and efficacy of anhydrous crystalline maltose (ACM) for treatment of dry mouth. DESIGN: ACM was delivered orally as a 200-mg lozenge given three times daily over a 12-week (study Alpha) or 24-week (study Omega) period to a total of 22 and 97 subjects, respectively. All participants had prominent complaints of persistent dry mouth associated with primary Sjögren's syndrome. Patients were examined every 4 weeks in study Alpha and every 6 weeks in study Omega. SETTINGS: Patients were seen in outpatient clinics at a total of 33 sites within the United States. OUTCOME MEASURES: Unstimulated whole saliva output, a measure of basal salivary gland function, was determined at each visit. Symptoms associated with oral and ocular dryness were assessed at the same time with the use of 100-mm visual analog scales. Safety was assessed by physical examination and laboratory studies. RESULTS: During these clinical trials, a majority of subjects demonstrated an increase in unstimulated whole saliva output and the treatment exhibited an excellent safety profile. The ACM treatment in study Omega led to significant improvement in several subjective measures of oral and ocular comfort. CONCLUSIONS: In these two studies, ACM lozenges administered three times daily for 12 or 24 weeks improved salivary output and decreased complaints of dry mouth and eyes. Side effects were minimal, and treatment was without significant adverse events. This safe and simple intervention may provide clinical benefit to individuals with distressing dry mouth symptoms.
Authors:
P C Fox; M J Cummins; J M Cummins
Related Documents :
7517824 - Chronic pain--challenge and response.
7046604 - A randomised controlled trial to compare local with general anaesthesia for short-stay ...
8080674 - Tropisetron compared with a metoclopramide-based regimen in the prevention of chemother...
22079524 - The effects of gait impairment with and without freezing of gait in parkinson's disease.
24697304 - Self-transcendence, spiritual perspective, and sense of purpose in family caregiving re...
12617274 - The role of helplessness as mediator between neurological disability, emotional instabi...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of alternative and complementary medicine (New York, N.Y.)     Volume:  7     ISSN:  1075-5535     ISO Abbreviation:  J Altern Complement Med     Publication Date:  2001 Feb 
Date Detail:
Created Date:  2001-03-14     Completed Date:  2001-05-31     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9508124     Medline TA:  J Altern Complement Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  33-43     Citation Subset:  IM    
Affiliation:
Amarillo Biosciences, Incorporated, TX 60612, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Female
Humans
Male
Maltose / administration & dosage,  therapeutic use*
Middle Aged
Sjogren's Syndrome
Treatment Outcome
United States
Xerostomia / prevention & control*
Chemical
Reg. No./Substance:
69-79-4/Maltose

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Assessment of outcomes at alternative medicine cancer clinics: a feasibility study.
Next Document:  Chronically ill patients treated by spiritual healing improve in quality of life: results of a rando...